-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to Chinese state media reports on November 3, China's national medical insurance drug catalogue will be adjusted in 2022, opening a separate declaration channel for rare disease drugs to support their priority entry into the medical insurance drug catalogue
.
Up to now, 45 rare disease drugs have been included in China's national medical insurance drug list, covering 26 rare diseases
.
According to data from the China Alliance for Rare Diseases, there are more than 20 million patients with various rare diseases in China, and more than 200,000
new patients are added every year.
The National Health Insurance Administration reduces the price
of drugs for rare diseases by negotiating access to rare disease drugs.
Since 2018, 19 new drugs for rare diseases have been added to the medical insurance drug list through negotiation, with an average price reduction of 52.
6%.
Establish a monitoring mechanism for the supply of drugs for rare diseases, improve the level of research and development and industrialization of drugs for rare diseases, support the participation of traditional Chinese medicine in the prevention and treatment of rare diseases, and promote the establishment of normal shortage drug reserves at the central and local levels.
.
.
According to the Ministry of Industry and Information Technology, China has taken a series of measures to improve the level of
drug protection for rare diseases.
According to reports, in the next step, China will continue to explore and improve the drug guarantee mechanism for rare diseases, continue to promote the adjustment of the national medical insurance drug catalog, improve the negotiation drug allocation mechanism, and at the same time strengthen policy convergence, give play to the multiple protection functions of basic medical insurance, serious illness insurance and medical assistance, and strive to provide better protection
for patients with rare diseases.
(End)
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body). 
